Immunogenicity (ADA, nAbs)
Our laboratory provides services for the assessment of immunogenicity, including the development and validation of assays for anti-drug antibodies (ADA) and neutralising antibodies (nAbs). We apply a tiered approach to evaluate the immunogenic potential of biotherapeutics, supporting immune response assessments.
Immunogenicity (ADA, nAbs)
Key Services:
- Development of tailored assays for ADA and nAbs
- Method validation to support immune response assessment
- Immunogenic potential is assessed using a structured, tiered approach: initial screening, confirmatory, and titre experiments, with statistical analysis to inform cut point calculations
ADA and neutralising antibody assays performed on validated MSD platforms
Applications:
- Assessment of antigenicity in new drug candidates
- Investigation of immune responses
Instrumentation: We utilize a range of advanced technologies, including:
- MSD (MESO QuickPlex SQ 120MM Model 1300)
- Tecan Infinite M200 Pro and Infinite M Nano
- Agilent BioTek ELx808